Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
FimmCyte logo — First disease modifying treatment for Endometriosis.

FimmCyte

First disease modifying treatment for Endometriosis.

Founded 2022 Switzerland Basel, Switzerland 7 employees Seed Total: $1.30M Biotechnology, Health Care

General Information

Company Name FimmCyte
Founded Year 2022
Location Switzerland Basel, Switzerland
Employees 7
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with FimmCyte. To contact FimmCyte, visit fimmcyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does FimmCyte compare?

A PDF of FimmCyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting FimmCyte soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About FimmCyte

FimmCyte, founded in 2022 and headquartered in Switzerland, is a pioneering company in the Biotechnology and Health Care sectors. The company is noteworthy for its groundbreaking approach to addressing endometriosis, a debilitating condition affecting millions globally, with what they claim to be the “First disease modifying treatment for Endometriosis.”

Recently, FimmCyte secured a Fr.1.00M Convertible Note investment on 01 February 2024 from the UZH Life Sciences Fund. This infusion of capital will likely bolster their R&D capabilities and expedite the regulatory pathway. The involvement of the UZH Life Sciences Fund not only provides financial support but also serves as an endorsement of the company’s potential to significantly impact the treatment landscape of endometriosis. Investors should monitor FimmCyte for its capacity to innovate within a healthcare segment ready for disruption and socially impactful solutions.

Business keywords: Endometriosis treatment, Disease modifying therapies, Fibro-inflammatory diseases, Healthcare innovation, Pharmaceutical development, Women's health, Medical research, Drug development, Chronic disease management, Therapeutic solutions, Biomedical advancements

Services & Products

Development of targeted immunotherapy solutions
Research on disease-modifying treatments for fibro-inflammatory diseases
Innovative therapies for endometriosis

Target Customers

Patients with endometriosis Individuals suffering from chronic fibro-inflammatory conditions Healthcare providers seeking advanced treatment options

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note Fr.1.00M 1
UZH Life Sciences Fund
01 Feb 2024
Round Undisclosed -
01 Sep 2023
Grant Fr.150.00K 1
Venture Kick
Venture Kick
01 Jul 2022
Spinout Fr.150.00K 1
Gebert Rüf Foundation
01 Feb 2022

Latest News

View All
10 most innovative Swiss startups to watch in 2024 and beyond! — Eu-startups
10 most innovative Swiss startups to watch in 2024 and beyond!
Eu-startups Mar 15, 2024

FimmCyte Alternatives & Competitors

View All Alternatives
FimmCyte vs
CV6 Therapeutics, (NI) Ltd.
CV6 Therapeutics, (NI) Ltd. United Kingdom

CV6 Therapeutics is dedicated to improving patients lives through the development of novel and innov...

Venture round
11 employees
Biotechnology, Health Care
FimmCyte vs
Vantage Biosciences
Vantage Biosciences United Kingdom

Transforming diabetic eye disease with an oral treatment

Seed
6 employees
Biotechnology, Health Care
FimmCyte vs
Evommune
Evommune United States

Developing innovative therapies that target key drivers of chronic inflammatory diseases.

69 employees
Biotechnology, Health Care
View all alternatives

FAQ About FimmCyte

First disease modifying treatment for Endometriosis.
FimmCyte was founded in 2022.
FimmCyte is headquartered in Basel, Switzerland.
FimmCyte operates in Biotechnology and Health Care. Its work centres on Endometriosis treatment, Disease modifying therapies, Fibro-inflammatory diseases and Healthcare innovation. Its customers include Patients with endometriosis, Individuals suffering from chronic fibro-inflammatory conditions and Healthcare providers seeking advanced treatment options.
FimmCyte has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
FimmCyte has approximately 7 employees.
FimmCyte has completed 4 funding rounds, raising a total of $1.30M. The latest funding stage is Seed.
FimmCyte offers: Development of targeted immunotherapy solutions, Research on disease-modifying treatments for fibro-inflammatory diseases, Innovative therapies for endometriosis.
Top alternatives and competitors to FimmCyte include CV6 Therapeutics, (NI) Ltd., Vantage Biosciences, Evommune, Yaqrit, Upstream Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FimmCyte and CV6 Therapeutics, (NI) Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for FimmCyte, https://bouncewatch.com/company/fimmcyte-1, updated 26 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes